Caplin Point Laboratories has entered into a license and distribution agreement with Cycle Pharmaceuticals, a limited company having its principal offices in Cambridge, UK. Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified liquid injectable products whereas Cycle Pharmaceuticals Limited shall be holding this ANDA and commercialize the same in USA. This is a product specific agreement for United States of America. Currently one product is featuring in the contract.
Caplin Point has already received milestone payment for one product and the product development cum dossier preparation have just commenced.
Cycle Pharmaceuticals is one of the niche global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
